FDA Approves Ibrutinib

The US Food and Drug Administration (FDA) approved ibrutininb in November 2013 for the treatment of relapsed mantle cell lymphoma. Ibrutinib is a new drug which was developed to specifically block a particular enzyme called the Bruton’s tyrosine kinase which goes by the acronym, BTK. This enzyme, BTK, is over-active in many types of malignancies […]